This is a sulopenem etzadroxil news story, published by Gizmodo, that relates primarily to FDA news.
For more sulopenem etzadroxil news, you can click here:
more sulopenem etzadroxil newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Gizmodo, you can click here:
more news from GizmodoOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
certain uncomplicated UTIs. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest urinary tract infections news, recurrent UTIs news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
uncomplicated UTIsGizmodo
•
78% Informative
The FDA approved Orlynvah for certain kinds of urinary tract infections that aren’t likely to respond to other drugs.
It contains a combination of sulopenem etzadroxil , which belongs to a subclass of antibacterials called penems.
Penems are synthetic antibiotics that has shown great promise in treating a wide variety of commonly resistant germs.
VR Score
72
Informative language
69
Neutral language
38
Article tone
informal
Language
English
Language complexity
64
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
5
Affiliate links
no affiliate links